DMAC vs JILL Comparison

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). J.Jill caters to a distinctive set of women, typically forty-five years and older, offering them various apparel products, footwear, and accessories, comprising shirts, dresses, tops and tees, sweaters, pants and jeans, jewelry, bags, belts, shoes, scarves, etc. The company's operating segments consist of its Retail channels, which derive maximum revenue, and Direct channels. Geographically, the majority of its revenue is derived from the United States.